stockportfolio.pro
Stocks / AXSM vs PEN
AXSM vs PEN
Axsome Therapeutics, Inc. and Penumbra, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Axsome Therapeutics, Inc. (AXSM) | Penumbra, Inc. (PEN) | |
|---|---|---|
| Market cap | $13.0B | $12.6B |
| Revenue (latest FY) | $638.50M | $1.40B |
| Net income (latest FY) | $-183.17M | $177.69M |
| Revenue growth (5y CAGR) | — | 20.2% |
| Net margin | -28.7% | 12.7% |
| Return on equity | -207.5% | 12.4% |
| P/E ratio | — | 73.8 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 8 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AXSM — free Open PEN — freeFrequently asked questions
Which is bigger, AXSM or PEN?
Axsome Therapeutics, Inc. is larger by market capitalization — $13.0B versus $12.6B.
Which grows faster, AXSM or PEN?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.